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ABSTRACT 
Objective: The objective of the present study was to formulate and evaluate a gastro-retentive in situ gelling system of metronidazole. 
Methods: Sodium alginate based metronidazole floating in situ gelling systems were prepared by dissolving sodium alginate in distilled water, to 
which varying concentrations of viscosity enhancing polymer (methylcellulose, hydroxypropyl methylcellulose, or sodium carboxymethylcellulose), 
drug, and gas-forming agent (s) as calcium carbonate/and sodium bicarbonate were added and dissolved by stirring. Prepared formulae were 
evaluated for viscosity, floating behavior, drug content and in vitro drug release behavior. 
Results: Formulation variables such as the type and concentration of viscosity enhancing polymer, the concentration of gas-forming agents affected 
the formulation viscosity, floating behavior and in vitro drug release. 
Conclusion: The prepared in situ gelling formulations of metronidazole could float in the gastric conditions and release the drug in controlled 
manner. The prepared formulations appear to be promising drug delivery system for localized delivery of metronidazole for better treatment of 
peptic ulcer disease caused by H. pylori. 
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INTRODUCTION 
Over the past few years, the development of floating in situ gel 
systems has received considerable attention, mainly because of the 
advantages shown by these systems such as the ease of 
administration along with the ability of providingcontrolled and 
prolonged action compared to conventional drug delivery systems; 
these factors led to reduced frequency of administration and 
therefore improved patient compliance and comfort [1]. 
The in situ gel dosage form is a liquid before administration but 
converts into a gel that floats on gastric contents as it comes in 
contact with it. [2]Such gel conversions is due to one or more 
mechanisms such as physiological stimuli (e. g., temperature and 
pH), physical changes in biomaterials (e. g., diffusion of solvent and 
swelling), and chemical reactions (e. g., enzymatic, ionic and photo-
initiated polymerization)[3]. 
Floating in situ gel drug delivery systems have been used to deliver 
many drugs which are used either for their systemic or for their local 
effects in the stomach [4]. 
Helicobacter pylori (H. pylori), one of the causative agents for 
bacterial infections in humans is responsible for several 
gastrointestinal diseases such as gastritis, gastric ulcer and gastric 
cancer.[5] H. pylori infection can be effectively cured by treatment 
with various combinations of antibiotics. More specifically, 
metronidazole, an effective antiprotozoal and antibacterial drug, is 
commonly used in conjunction with either amoxicillin or 
clarithromycinand an acid suppressor (usually a proton pump 
inhibitor) or an H2
In an attempt to prolong gastric residence time of metronidazole and 
therefore to improve its local effects in the stomach and achieve 
better eradication of H. pylori, certain floating systems were 
developed, including floating metronidazole beads [8-10]. Pellets 
[11]. And tablets [12, 13]. 
-receptor antagonist (e. g. ranitidine) to eradicate 
H. pylori infection [6, 7]. 
The objective of the present study was to develop metronidazole 
floating in-situ gel that remains in the stomach, resulting in an 
increased gastric residence time and thus increases local 
concentration of the drug for complete eradication of H. pylori. 
MATERIALS AND METHODS 
Materials 
Metronidazole (supplied by Samarra Drug Industry, Iraq), sodium 
alginate(SA) and hydroxylpropyl methylcellulose (HPMC) 
(Himedialaboratories, India), methylcellulose (MC) (BDH 
laboratories, UK), sodium carboxymethylcellulose (NaCMC) (BDH 
laboratories, UK), sodium bicarbonateand calcium carbonate 
(Riedel-deltaen, Germany). All other reagents were of analytical 
grade.  
Methods 
Preparation of In-situ Gel 
Floating in situ gel formulations of metronidazole were prepared 
using compositions given in Table 1. In around 75% water, a 
measured quantity of sodium alginate (SA) required to make a 2 % 
(w/v) solution was dissolved in distilled water at 60○C using a 
heating magnetic stirrer (Velp Scientific a HSC, Italy). After cooling 
to below 40○
Evaluation 
C, appropriate amounts of polymer (MC, HPMC or 
NaCMC), methyl paraben and propyl paraben (ratio of 9:1), the drug, 
metronidazole (MTZ),along with gas generating agent (calcium 
carbonate with or without sodium bicarbonate) were dissolved/ 
dispersed uniformly into the sodium alginate solution with 
continuous stirring. The stirring was continued after complete 
addition until a uniform dispersion was obtained and the dispersion 
was allowed to cool at room temperature. Finally, the volume was 
adjusted to 100% with distilled water and the mixture was mixed 
well to get the final preparation which was stored in amber color 
bottles until further use [14]. 
Determination of drug content 
Accurately, 10 mL of formulation (containing the equivalent of 250 
mg metronidazole) from different batches was measured and 
transferred to 100 mL volumetric flask. To this 50-70 mL of 0.1 N 
HCl was added and sonicated for 30 min. Volume was adjusted to 
100 mL. Complete dispersion of contents was ensured visually and 
the dispersion was filtered using Whatman Filter Paper. From this 
solution, 10 mL of sample was withdrawn and diluted to 100 mL 
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with 0.1 N HCl. Contents of metronidazole was measured at 
maximum absorbance at 278 nm using UV-Visible 
Spectrophotometerat (Biotech eng. UV-9200, UK) [15]. 
pH Measurement 
The pH of the prepared formulations was measured using a 
calibrated digital pH meter (Schott Gerate, Germany)[16]. 
In-vitro gelation study  
To evaluate the formulations for their in-vitro gelling capacity, 
accurately measured 10 mL of formulation was added to 100 mL of 
0.1N hydrochloric acid (HCl, pH 1.2) at 37○
(+) Gels after few minutes, dispersed rapidly 
C in a beaker with mild 
agitation that avoids breaking of formed gel. The in vitro gelling 
capacity was graded in three categories on the basis of stiffness of 
formed gel, gelation time and time period for which the formed gel 
remains as such. 
(++) Gelation immediate remains for few hours 
(+++) Gelation immediate remains for an extended period [17]. 
Measurement of viscosity of in-situ gelling system 
Viscosity of the dispersion was determined using a Brookfield digital 
viscometer (NDJ-5S Viscometer). The samples (200 mL) were sheared at 
a rate of 100 rpm/min using spindle number 2 at room temperature. 
Viscosity measurement for each sample was done in triplicate, with each 
measurement taking approximately 30 seconds [18]. 
 
Table 1: Composition of metronidazole floating in situ gel formulations* 











F1 0.6   2 0 
F2 0.6   1.5 0.5 
F3 0.6   1 1 
F4 0.8   1.5 0.5 
F5  0.6  2 0 
F6  0.6  1.5 0.5 
F7  0.6  1 1 
F8  0.8  1.5 0.5 
F9   0.6 2 0 
F10   0.6 1.5 0.5 
F11   0.6 1 1 
F12   0.8 1.5 0.5 
*All formulations were composed of metronidazole (2.5 % w/v), sodium alginate (2% w/v), methyl paraben (0.09 % w/v) and propyl paraben 
(0.01% w/v). 
 
In vitro floating study 
The in-vitro floating study was carried out by introducing 10 mL of 
formulation into a beaker containing 100 ml of 0.1N HCl, (pH 1.2) at 
37○
The time the formulation took to emerge on the medium surface 
(floating lag time) and the time the formulation constantly floated on 
surface of the dissolution medium (duration of floating) were 
recorded [19]. 
C without much disturbance. 
In vitro drug release study 
The dissolution studies were performed in triplicate using a type II 
(paddle method) dissolution apparatus. The dissolution medium 
used was 900 ml of 0.1 N HCl (pH 1.2), maintained at 37 ºC. The 
stirring rate was adjusted to 50 rpm. This speed was believed to 
simulate the in vivo existing mild agitation and was slow enough to 
avoid the breaking of gelled formulation. At predetermined time 
intervals, 10 mL samples were withdrawn and replaced by fresh 
dissolution medium, filtered throughWhatman filter paper, diluted, 
and assayed at maximum absorbance at 278 nm using UV-Visible 
Spectrophotometer (Biotecheng. UV-9200, UK) [20, 21]. 
RESULTS AND DISCUSSION 
In this study, twelve formulations of sodium alginate based floating 
oral in-situ gelling system of metronidazole were prepared using 
sodium alginate as release-retarding gel-forming polymer. 
Different types of viscosity enhancing polymers (MC, HPMC, and 
NaCMC) were added to sodium alginate solution in an attempt to 
improve viscosity and to obtain slower drug release than those 
formulations containing sodium alginate alone. Calcium carbonate 
was used as a source of calcium ions and as a gas generating agent, it 
was used in different concentrations to determine its optimum 
concentration; in addition, sodium bicarbonate, also used in 
different concentrations, was included in some formula as an 
additional gas generating agent to enhance floating behavior of the 
in situ gelling systems of metronidazole. 
Drug content 
The percent drug content for all formulations was determined and 
are shown in Table 2. The drug content was found to bein the range 
of 92-98%for all the formulations indicating uniform distribution of 
drug. 
pH Measurement 
Measurement of pH is very important for oral preparations; 
otherwise it leads to irritation to the throat. All the formulation has a 
pH around neutral or slightly alkali. The pH of formulations was 
found in the range of 7.2-7.95 as shown in Table 2. 
In Vitro gelation study  
Gelling studies were carried out using 0.1N HCl (pH 1.2) and the 
obtained data were represented in Table 2. All formulations showed 
immediate gelation upon contact with acidic medium and the 
formed gel preserved their integrity.  
Gelation occurs when the insoluble calcium carbonate solubilizes 
when it comes in contact with acidic medium releasing carbon 
dioxide and calcium ions. The calcium ions interact with the anionic 
polymer (sodium alginate) in the formulation causing instantaneous 
gelation and provide a gel barrier that restricts drug release [22]. 
Formulations containing calcium carbonate alone produce stiffer 
floating in situ gels than those containing CaCO3andNaHCO3. This is 
due to the internal ionotropic gelation effect of calcium on sodium 
alginate. In comparison, increasing the amounts of sodium 
bicarbonates in the formulations reduced gel integrity and produced 
gels with loose structural appearance. Similar observations were 
noted by Hasan et al. [23] who concluded that as the percentage of 
NaHCO3 increases, the gel integrity decreases.  
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The formulation should have an optimum viscosity that will allow 
ease of administration and swallowing as a liquid and produces 
satisfactorygel strength for use as a delivery vehicle. Results of 
viscosity for formulations F1 to F12 are shown in Table 2. 
The formulations showed a viscosity order of NaCMC > MC > HPMC. 
In addition to the influence of the type of viscosity enhancing 
polymer added, it was observed that increasing the concentration of 
the viscosity enhancing polymer in the formulation simultaneously 
increased the viscosity for all polymer types studied. 
Increasing calcium carbonate content in the formulation increased 
the viscosity at all polymer types studied. Since the calcium 
carbonate is present in the formulations as insoluble dispersion, an 
increase in its concentration proportionally increased the number of 
particles dispersed, thus contributing to increased viscosity. [24]
 












F1 96.22 7.3 +++ 10 > 12 hr 401.86 
F2 98.00 7.26 +++ < 1 > 12 hr 360.55 
F3 95.75 7.8 +++ < 1 > 12 hr 299.90 
F4 94.78 7.23 +++ < 1 > 12 hr 730.56 
F5 96.20 7.40 +++ 5 > 12 hr 218.35 
F6 92.00 7.58 +++ < 1 > 12 hr 214.7 
F7 93.50 7.2 +++ < 1 > 12 hr 198.55 
F8 94.20 7.32 +++ < 1 > 12 hr 320.3 
F9 95.20 7.43 +++ 6 > 12 hr 838.96 
F10 96.00 7.95 +++ < 1 > 12 hr 742.20 
F11 94.25 7.27 +++ < 1 > 12 hr 641.40 
F12 95.00 7.93 +++ < 1 > 12 hr 1567.16 
 
In vitro Floating study 
The formulated floating in situ gelling system of metronidazole 
employed NaHCO3 orCaCO3
Regarding the floating lag time, it was observed that formulae 
containing NaHCO
 as a gas-generating agent. The in 
vitrofloatingtest revealedthe ability of all formulae to maintain 
buoyant for more than 12 h(Table 2 and Figure1).  
3 had instantaneous floating behavior and had 
significantly shorter (p < 0.05) floating lag times than formulae 
containing CaCO3 alone as a gas-generating agent. The basic 
mechanism behind floating was because calcium carbonate 
solubilized and effervesced upon contact with acidic medium, 
releasing calcium ions and carbon dioxide (CO2). The evolved CO2 
gas was entrapped in the gel causing floating. Incorporation of 
sodium bicarbonates improves floating behavior by providing an 
additional source for CO2
The observed behavior suggests that the gel formed by the 
combination of sodium alginate with the investigated polymers, 
enabled efficient entrapment of CO
 gasgeneration [25, 26]. 
2 
In vitro drug release study 
gas producing a buoyant 
preparation with shorter floating lag time which can retain in the 
stomach for a longer time period and assist controlled released of 
the drug. 
The in vitro release study of metronidazole from all twelve formulae 
in 0.1 N HCl (pH 1.2)was conducted for a period of 6 hours and the 
results were shown in figure 2. The highest drug release of 89.81 % 
was observed with formula F7 (SA 2 %, HPMC 0.6 %, CaCO3 0.5 % 
and NaHCO3 1.5 %) and the lowest drug release of 55.40 %was 
observed with formula F9 (SA 2 %, NaCMC 0.6 %, CaCO3
The influence of using different types of viscosity enhancing 
polymers(MC, HPMC and NaCMC) with sodium alginate on in vitro 
drug release is shown in Figure 2 a, b and c, respectively. The pattern 
of drug release seen from formulae containing MC (F1 through F4, 
figure 2a), HPMC (F5 through F8, figure 2b) and NaCMC (F9 through 
F12, figure 2c) showed that the release of metronidazole was 
different when using different types of polymers and was in the 
following order: HPMC > MC > NaCMC. This suggests that the choice 
of the polymer base added is of obvious importance for achieving a 
desired drug release. The higher viscosity of NaCMC compared to MC 
and HPMC promote the formation of highly viscous gels upon 
contact with aqueous fluids which will produce more retardation in 
drug release rate. 
 2 %). The 
release of drug from these formulae was characterized by an initial 
phase of high release (burst effect) followed by a second phase of 
moderate release. This bi-phasic pattern of release is a characteristic 
feature of matrix diffusion kinetics [27]. 
 
 
Fig. 1: Photographs taken during the in vitro floating study of 
Formulae (F1-F12) in 100 mL 0.1 N HCl (pH 1.2) 
 
Besides the polymer type, the polymer concentration can control the 
drug release. In the MC series (figure 2 a), formula F4 containing 0.8 
% of MC released about 72.97 % in 6 hours compared to 78.02 % 
release seen with formula F2 containing 0.6 % of MC. In a similar 
way, formula F8and formula F12 (figure 2, b and c) containing 0.8 % 
HPMC and 0.8 % NaCMC, respectively released about 82.18 % and 
67.20 % of metronidazole compared to 87.79 %and 70.23 % 
released by formula F6 and F10 containing 0.6 % of HPMC and 0.6 % 
NaCMC. It can be concluded that an increase in concentration of 
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viscosity enhancing polymer resulted in decreased cumulative drug 
release, this is a reflection of increased gel strength seen when using 
higher polymeric concentrations due to more available polymeric 
chains for crosslinking with the calcium ion. [28] 
Calcium carbonate (0.5–2 %) was used as a gas generating agent and 
as a source of cations for gelation in the formulation. Using a 
concentration of 0.5 % CaCO3
As shown in figure 2, formulae F1, F5 and F9 containing CaCO
 produced desired floating duration 
but higher concentrations were used in an attempt to have more 
retarded drug release.  
3 in a 
concentration of 2 % had slower drug release profiles than the rest 
of formulae containing lower percentages of CaCO3
  
. This indicates 
that the drug release decreased as the concentration of calcium 
carbonate in the formulation was increased. Such behavior may be 
attributed to the fact that as the concentration of calcium ions 
increases, cross-linking also increases leading to formation of a 
stronger gel, which results in more restricted and slower drug 
release. These results are in good agreement with the observations 





Fig. 2: Comparison of in vitro dissolution profiles of F1 to F12. 
a) Formulations containing MC, b) Formulations containing 
HPMC, and, c) Formulations containing NaCMC. 
 
Regarding the effect of sodium bicarbonate on drug release, 
comparing the drug release profiles of formulations containing 
sodium bicarbonate (F2 to F4, figure 2a) to formulations without 
sodium bicarbonate (F1), a proportional increase in drug release 
profile can be observed with increasing amounts of sodium 
bicarbonate. Such observations were not only observed for formula 
containing MC but were also apparent with formulaecontaining 
HPMC or NaCMC.  
The reason for the increase in drug release when using higher 
amounts of sodium bicarbonate may be because of weaker gelation 
properties occurring with the presence of sodium ions in the 
formulation compared to stronger gelation effect produced in the 
presence of calcium ions. 
CONCLUSION 
In the present study, various in situ gelling liquid oral formulations 
of metronidazole were prepared. The study has shown that by 
modifying parameters like the type and concentration of viscosity 
enhancing polymer, concentration of gas generating agent, the 
release can be modulated to the desired rate.  
By observing various evaluation parameters for the studied 
formulations, it can be stated that incorporation of sodium 
bicarbonate in an appropriate amount was able to shorten the 
floating lag time and variation in concentration of calcium carbonate 
influences viscosity and drug release behavior from in situ gel. 
The prepared floating in situ gel of metronidazole has the feasibility 
of sustaining the drug release while remaining in the stomach. It 
appears to be promising as a stomach specific delivery system of 
metronidazole for better treatment of peptic ulcer disease caused by 
H. pylori. 
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